Thr3

Site Information
_____MktPADtGFA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3191419

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 )
Disease tissue studied:	breast cancer ( 3 , 5 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , leukemia ( 15 ) , chronic myelogenous leukemia ( 15 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 , 3 ) , BT-20 (breast cell) ( 5 ) , BT-549 (breast cell) ( 5 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 6 ) , Flp-In T-Rex-293 (epithelial) ( 6 ) , H2009 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , HCC1359 (pulmonary) ( 5 ) , HCC4006 (pulmonary) ( 5 ) , HCC827 (pulmonary) ( 5 ) , HeLa (cervical) ( 8 , 10 , 12 , 13 ) , Jurkat (T lymphocyte) ( 4 , 9 , 11 , 14 ) , K562 (erythroid) ( 15 ) , LCLC-103H (pulmonary) ( 5 ) , MDA-MB-231 (breast cell) ( 5 ) , MDA-MB-468 (breast cell) ( 5 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H157 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 5 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	ischemia ( 3 ) , selumetinib ( 2 ) , vemurafenib ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
7	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
8	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
9	Mulhern D (2011) CST Curation Set: 12681; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
10	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
11	Possemato A (2009) CST Curation Set: 8351; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
12	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
13	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
14	Possemato A (2008) CST Curation Set: 4737; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
15	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info